Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 49Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 14Lymphoma, B-Cell, Marginal Zone 13Lymphoma 9Recurrence 7Lymphoma, Non-Hodgkin 7Neoplasms 6Lymphoma, Mantle-Cell 5Lymphoma, B-Cell 4Neoplasms, Plasma Cell 3Neoplasm, Residual 3Lymphoma, T-Cell, Peripheral 3Smoldering Multiple Myeloma 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Vitamin D Deficiency 1Peripheral Nervous System Diseases 1Paraproteinemias 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Diseases 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Corneal Diseases 1Cardiotoxicity 1Blood Protein Disorders 1

Interventions

nirogacestat 1Tissue Banks 1Lenalidomide 1Dexamethasone 1Clonal Hematopoiesis 1Chromatin Immunoprecipitation Sequencing 1Blood Cell Count 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Paraproteinemias × Lenalidomide × Clear all
NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Hellenic Society of Hematology

Phase 1/2 Recruiting
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡